Epigenetics of estrogen receptor-negative primary breast cancer

References

• American Cancer Society. Cancer Facts Figures. American Cancer Society, GA, USA, 9 (2009).
   Google Scholar
• Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J. Mammary Gland Biol. Neoplasia14(1), 67–78 (2009).
   PubMed Web of Science ®Google Scholar
• Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol.19(3), 165–171 (2009).
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Estrogen receptors: role in breast cancer. Crit. Rev. Clin. Lab. Sci.43(4), 325–347 (2006).
   PubMed Web of Science ®Google Scholar
• Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev.29(5), 419–426 (2005).
   PubMedGoogle Scholar
• Li Q, Eklund AC, Juul N et al. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One5(12), e15031 (2010).
   Google Scholar
• Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol.28(16), 2784–2795 (2010).
   PubMed Web of Science ®Google Scholar
• Saxena NK, Sharma D. Epigenetic reactivation of estrogen receptor: promising tools for restoring response to endocrine therapy. Mol. Cell. Pharmacol.2(5), 191–202 (2010).
   PubMedGoogle Scholar
• Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev.23(7), 781–783 (2009).
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med.17(3), 330–339 (2011).
   PubMed Web of Science ®Google Scholar
• Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol.9, 76 (2008).
   PubMed Web of Science ®Google Scholar
• Frankel LB, Christoffersen NR, Jacobsen A et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem.283(2), 1026–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65(16), 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H et al. miR-21-mediated tumor growth. Oncogene26(19), 2799–2803 (2007).
   PubMed Web of Science ®Google Scholar
• Sunami E, Shinozaki M, Sim MS et al. Estrogen receptor and HER2/ν status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res.10(3), R46 (2008).
   PubMedGoogle Scholar
• van Hoesel AQ, van de Velde CJ, Kuppen PJ et al. Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer. Breast Cancer Res. Treat.131(3), 859–869 (2012).
   PubMed Web of Science ®Google Scholar
• Schinke C, Mo Y, Yu Y et al. Aberrant DNA methylation in malignant melanoma. Melanoma Res.20(4), 253–265 (2010).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell128(4), 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. J. Nat. Biotechnol.28(10), 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis31(1), 27–36 (2010).
   PubMed Web of Science ®Google Scholar
• Huang TH, Esteller M. Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb. Perspect. Biol.2(9), A004515 (2010).
   Google Scholar
• Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol. Oncol.4(3), 242–254 (2010).
   PubMed Web of Science ®Google Scholar
• Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics9(12), 1879–1902 (2008).
   PubMed Web of Science ®Google Scholar
• Pathiraja TN, Stearns V, Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer–role in treatment response. J. Mammary Gland Biol. Neoplasia15(1), 35–47 (2010).
   PubMed Web of Science ®Google Scholar
• Shinozaki M, Hoon DS, Giuliano AE et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin. Cancer Res.11(6), 2156–2162 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma G, Mirza S, Parshad R et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin. Biochem.43(4–5), 373–379 (2010).
   PubMed Web of Science ®Google Scholar
• Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann. N. Y. Acad. Sci.1137, 171–174 (2008).
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science293(5532), 1074–1080 (2001).
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell128(4), 693–705 (2007).
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science298(5595), 1039–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev.16(22), 2893–2905 (2002).
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature439(7078), 871–874 (2006).
   PubMed Web of Science ®Google Scholar
• Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development132(21), 4645–4652 (2005).
   PubMed Web of Science ®Google Scholar
• Davis BN, Hata A. microRNA in cancer – the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer1(11), 1100–1114 (2010).
   PubMedGoogle Scholar
• Calin GA, Croce CM. MicroRNA–cancer connection: the beginning of a new tale. Cancer Res.66(15), 7390–7394 (2006).
   PubMed Web of Science ®Google Scholar
• Asaga S, Kuo C, Nguyen T et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem.57(1), 84–91 (2011).
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA14(11), 2348–2360 (2008).
   PubMed Web of Science ®Google Scholar
• Lapidus RG, Nass SJ, Butash KA et al. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res.58(12), 2515–2519 (1998).
   PubMed Web of Science ®Google Scholar
• Ottaviano YL, Issa JP, Parl FF et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res.54(10), 2552–2555 (1994).
   PubMed Web of Science ®Google Scholar
• Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res.55(11), 2279–2283 (1995).
   PubMed Web of Science ®Google Scholar
• Yan L, Nass SJ, Smith D et al. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-α (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther.2(5), 552–556 (2003).
   PubMed Web of Science ®Google Scholar
• Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet.25(3), 269–277 (2000).
   PubMed Web of Science ®Google Scholar
• Leu YW, Yan PS, Fan M et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res.64(22), 8184–8192 (2004).
   PubMed Web of Science ®Google Scholar
• Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA. Mol. Cell. Biol.29(13), 3783–3790 (2009).
   PubMed Web of Science ®Google Scholar
• Park SY, Kwon HJ, Lee HE et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch.458, 73–84 (2011).
   PubMed Web of Science ®Google Scholar
• Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J. Mol. Diagn.10(1), 93–101 (2008).
   PubMed Web of Science ®Google Scholar
• Chen KM, Stephen JK, Raji U, Worsham MJ. Delineating an epigenetic continuum for initiation, transformation and progression to breast cancer. Cancers (Basel)3(2), 1580–1592 (2011).
   PubMedGoogle Scholar
• Pasquali L, Bedeir A, Ringquist S et al. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett.257(1), 136–144 (2007).
   PubMed Web of Science ®Google Scholar
• Hoque MO, Prencipe M, Poeta ML et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol. Biomarkers Prev.18(10), 2694–2700 (2009).
   PubMed Web of Science ®Google Scholar
• Marzese DM, Gago FE, Vargas-Roig LM, Roqué M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol. Cell. Probes24(5), 271–280 (2010).
   PubMed Web of Science ®Google Scholar
• van Hoesel AQ, van de Velde CJH, Kuppen PJK et al. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. Breast Cancer Res. Treat. doi:10.1007/s10549-012-2038-0 (2012) (Epub ahead of print).
   Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA96(15), 8681–8686 (1999).
   PubMed Web of Science ®Google Scholar
• Kusano M, Toyota M, Suzuki H et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virus. Cancer106(7), 1467–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Tanemura A, Terando AM, Sim MS et al. CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res.15(5), 1801–1807 (2009).
   PubMed Web of Science ®Google Scholar
• Fang F, Turcan S, Rimner A et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med.3(75), 75ra25 (2011).
   PubMed Web of Science ®Google Scholar
• Jing F, Yuping W, Yong C et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol.31(4), 321–331 (2010).
   PubMedGoogle Scholar
• Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer7, 15 (2008).
   PubMed Web of Science ®Google Scholar
• Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann. N. Y. Acad. Sci.1014, 155–163 (2004).
   PubMed Web of Science ®Google Scholar
• Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol.1(6), A003129 (2009).
   PubMed Web of Science ®Google Scholar
• Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol.115(1), 85–98 (2001).
   PubMed Web of Science ®Google Scholar
• Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer92(3), 404–408 (2001).
   PubMed Web of Science ®Google Scholar
• Caldeira JRF, Prando EC, Quevedo FC, Neto FAM, Rainho CA, Rogatto SR. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer6, 48 (2006).
   PubMed Web of Science ®Google Scholar
• Nass SJ, Herman JG, Gabrielson E et al. Aberrant methylation of the estrogen receptor and E-cadherin in 5’ CpG islands increases with malignant progression in breast cancer. Cancer Res.60(16), 4346–4348 (2000).
   PubMed Web of Science ®Google Scholar
• Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J. Pathol.218(2), 265–272 (2009).
   PubMed Web of Science ®Google Scholar
• de Maat MF, Narita N, Benard A et al. Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. Am. J. Pathol.177(5), 2347–2356 (2010).
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res.59(21), 5438–5442 (1999).
   PubMed Web of Science ®Google Scholar
• Feng W, Shen L, Wen S et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res.9(4), R57 (2007).
   PubMed Web of Science ®Google Scholar
• Holm K, Hegardt C, Staaf J et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res.12(3), R36 (2010).
   PubMed Web of Science ®Google Scholar
• Flanagan JM, Cocciardi S, Waddell N et al. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet.86(3), 420–433 (2010).
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Miller N, Devaney A et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/ν receptor status in breast cancer. Breast Cancer Res.11(3), R27 (2009).
   PubMed Web of Science ®Google Scholar
• Orlando L, Schiavone P, Fedele P et al. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat. Rev.36(Suppl. 3), S67–S71 (2010).
   PubMed Web of Science ®Google Scholar
• Mori T, Martinez SR, O’Day SJ et al. Estrogen receptor-α methylation predicts melanoma progression. Cancer Res.66(13), 6692–6698 (2006).
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Das PM, Spoelstra NS et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer9, 317 (2010).
   PubMed Web of Science ®Google Scholar
• Issa JP, Kantarjian HM. Targeting DNA methylation. Clin. Cancer Res.15(12), 3938–3946 (2009).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer109(6), 1133–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Munster PN, Thurn KT, Thomas S et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer104(12), 1828–1835 (2011).
   PubMed Web of Science ®Google Scholar
• Fan J, Yin WJ, Lu JS et al. ER α negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol.134(8), 883–890 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res.66(12), 6370–6378 (2006).
   PubMed Web of Science ®Google Scholar
• Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res. Treat.81(3), 177–186 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor α (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther.6(1), 64–69 (2007).
   PubMed Web of Science ®Google Scholar
• Yang X, Ferguson AT, Nass SJ et al. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res.60(24), 6890–6894 (2000).
   PubMed Web of Science ®Google Scholar
• Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J.50(4), 455–463 (2009).
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res.69(9), 3802–3809 (2009).
   PubMed Web of Science ®Google Scholar
• Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA100(20), 11606–11611 (2003).
   PubMed Web of Science ®Google Scholar
• Xiong J, Yu D, Wei N et al. An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples. FEBS J.277(7), 1684–1694 (2010).
   PubMed Web of Science ®Google Scholar
• Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol.21(5), 1132–1147 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem.283(45), 31079–31086 (2008).
   PubMed Web of Science ®Google Scholar
• Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat.120, 581–592 (2010).
   PubMed Web of Science ®Google Scholar